Jan Köster

34.2k total citations · 2 hit papers
190 papers, 8.5k citations indexed

About

Jan Köster is a scholar working on Molecular Biology, Neurology and Cancer Research. According to data from OpenAlex, Jan Köster has authored 190 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Molecular Biology, 80 papers in Neurology and 58 papers in Cancer Research. Recurrent topics in Jan Köster's work include Neuroblastoma Research and Treatments (80 papers), Cancer, Hypoxia, and Metabolism (35 papers) and Epigenetics and DNA Methylation (18 papers). Jan Köster is often cited by papers focused on Neuroblastoma Research and Treatments (80 papers), Cancer, Hypoxia, and Metabolism (35 papers) and Epigenetics and DNA Methylation (18 papers). Jan Köster collaborates with scholars based in Netherlands, United States and Germany. Jan Köster's co-authors include Rogier Versteeg, Jan J. Molenaar, Peter van Sluis, Dirk Geerts, Huib N. Caron, Richard Volckmann, Linda J. Valentijn, Arnoud Sonnenberg, Danny A. Zwijnenburg and Nancy E. Hasselt and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Jan Köster

185 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent ‘+4’ cell markers

2012 562 citations Richard Volckmann, Jan Köster et al. profile →
Differentiated Troy+ Chief Cells Act as Reserve Stem Cells to Generate All Lineages of the Stomach Epithelium

2013 395 citations Jan Köster et al. profile →

Peers

Countries citing papers authored by Jan Köster

Since Specialization

Citations

This map shows the geographic impact of Jan Köster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Köster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Köster more than expected).

Fields of papers citing papers by Jan Köster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Köster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Köster. The network helps show where Jan Köster may publish in the future.

Co-authorship network of co-authors of Jan Köster

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Köster. A scholar is included among the top collaborators of Jan Köster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Köster. Jan Köster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer 2025 ·Med ·(unknown), Mark P.G. Dings, Jan Köster, Mariëtte Labots, Emile D. Kerver, Anouk Jochems, Marjolein Y.V. Homs, Judith de Vos‐Geelen, Mathijs P. Hendriks, Michael W.T. Tanck, Johanna W. Wilmink, Hanneke W. M. van Laarhoven, Maarten F. Bijlsma	1
2	Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort 2024 ·Translational research ·(unknown), Mark P.G. Dings, (unknown), Arantza Fariña Sarasqueta, Cynthia Waasdorp, Gerrit K. Hooijer, Joanne Verheij, Jan Köster, Danny A. Zwijnenburg, Johanna W. Wilmink, Jan Paul Medema, Frederike Dijk, Hanneke W.M. van Laarhoven, Maarten F. Bijlsma	2
3	Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors 2024 ·Cell Reports Medicine ·Dennis S. Metselaar, Michaël H. Meel, (unknown), Aimée du Chatinier, (unknown), (unknown), (unknown), Mark C. de Gooijer, Marjolein Breur, Jan Köster, Sophie E. M. Veldhuijzen van Zanten, Marianna Bugiani, N. Franke, Alyssa Reddy, Pieter Wesseling, Gertjan J.L. Kaspers, Esther Hulleman	3
4	MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma 2023 ·Frontiers in Oncology ·Thomas F. Eleveld, (unknown), Linda Schild, (unknown), Lindy K. Alles, Marli E. Ebus, (unknown), Harm van Tinteren, Huib N. Caron, Jan Köster, Max M. van Noesel, Godelieve A.M. Tytgat, Selma Eising, Rogier Versteeg, M. Emmy M. Dolman, Jan J. Molenaar	6
5	How germline genes promote malignancy in cancer cells 2022 ·BioEssays ·(unknown), Jan Köster, Ans M. M. van Pelt, Dave Speijer, Geert Hamer	12
6	Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours 2022 ·European Journal of Cancer ·(unknown), Celine Chen, Ana Isabel Enríquez Rodríguez, Jan Köster, Michele Dowless, Stefan M. Pfister, David J. Shields, Louis F. Stancato, Gilles Vassal, Hubert Caron, Marlinde L. van den Boogaard, Anton G. Henssen, Jan J. Molenaar	9
7	DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma 2022 ·JCI Insight ·Thale Kristin Olsen, Cecilia Dyberg, (unknown), (unknown), Jelena Milosevic, Jane Ding, Jörg Otte, (unknown), Ida Hed Myrberg, Ellen M. Westerhout, Jan Köster, Rogier Versteeg, Han‐Fei Ding, Per Kogner, John Inge Johnsen, David B. Sykes, Ninib Baryawno	21
8	High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells 2021 ·Molecular Cancer Therapeutics ·(unknown), Laurel T. Bate-Eya, Lindy K. Alles, (unknown), (unknown), (unknown), (unknown), Linda Schild, Daphne Lelieveld, David A. Egan, (unknown), Ronald W. Stam, Jan Köster, Kelly C. Goldsmith, Jan J. Molenaar, M. Emmy M. Dolman	9
9	Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma 2021 ·Proceedings of the National Academy of Sciences ·Marlinde L. van den Boogaard, Rurika Oka, (unknown), Linda Schild, Marli E. Ebus, (unknown), Danny A. Zwijnenburg, Piet Molenaar, (unknown), M. Emmy M. Dolman, Anke H. W. Essing, (unknown), Thomas Helleday, Jarno Drost, Ruben van Boxtel, Rogier Versteeg, Jan Köster, Jan J. Molenaar	17
10	RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma 2018 ·Cancer Research ·Thomas F. Eleveld, Linda Schild, Jan Köster, Danny A. Zwijnenburg, Lindy K. Alles, Marli E. Ebus, Richard Volckmann, (unknown), Peter van Sluis, Rogier Versteeg, Jan J. Molenaar	40
11	Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma 2018 ·Cancer Research ·(unknown), (unknown), (unknown), Jan Köster, (unknown), (unknown), (unknown), Hermann Rohrer, Patrick N. Harter, Thomas Klingebiel, Julian D. Langer, Dirk Geerts, Dorothea Schulte	10
12	MELK Inhibition in Diffuse Intrinsic Pontine Glioma 2018 ·Clinical Cancer Research ·Michaël H. Meel, Mark C. de Gooijer, Míriam Guillén Navarro, (unknown), Marjolein Breur, Levi C.M. Buil, Laurine E. Wedekind, Jos W. R. Twisk, Jan Köster, Rintaro Hashizume, Eric H. Raabe, Ángel M. Carcaboso, Marianna Bugiani, Olaf van Tellingen, Dannis G. van Vuurden, Gertjan J.L. Kaspers, Esther Hulleman	32
13	SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer 2015 ·Clinical Cancer Research ·Thomas T. Vellinga, Tijana Borovski, Vincent C. J. de Boer, Szabolcs Fátrai, Susanne van Schelven, Kari Trumpi, André Verheem, Nikol Snoeren, Benjamin L. Emmink, Jan Köster, Inne H.M. Borel Rinkes, Onno Kranenburg	165
14	GPx2 Suppression of H2O2 Stress Links the Formation of Differentiated Tumor Mass to Metastatic Capacity in Colorectal Cancer 2014 ·Cancer Research ·Benjamin L. Emmink, Jamila Laoukili, Anna P. Kipp, Jan Köster, Klaas M. Govaert, Szabolcs Fátrai, André Verheem, Ernst J.A. Steller, Regina Brigelius‐Flohé, Connie R. Jiménez, Inne H.M. Borel Rinkes, Onno Kranenburg	77
15	FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma 2013 ·Cancer Research ·Evan E. Santo, Peter Stroeken, Peter van Sluis, Jan Köster, Rogier Versteeg, Ellen M. Westerhout	117
16	A NOTCH3 Transcriptional Module Induces Cell Motility in Neuroblastoma 2013 ·Clinical Cancer Research ·Johan van Nes, Alvin Chan, Tim van Groningen, Peter van Sluis, Jan Köster, Rogier Versteeg	33
17	Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer 2012 ·Clinical Cancer Research ·Kristel Kemper, Miranda Versloot, Katherine Cameron, Selçuk Çolak, Felipe de Sousa e Melo, Joan H. de Jong, (unknown), Louis Vermeulen, Rogier Versteeg, Jan Köster, Jan Paul Medema	76
18	Regulation of Cell Cycle Genes and Induction of Senescence by Overexpression of OTX2 in Medulloblastoma Cell Lines 2010 ·Molecular Cancer Research ·Jens Bunt, (unknown), Nancy E. Hasselt, Danny A. Zwijnenburg, Jan Köster, Rogier Versteeg, Marcel Kool	36
19	Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy 2009 ·Cancer Research ·Johannes H. Schulte, Soyoung Lim, Alexander Schramm, Nicolaus Friedrichs, Jan Köster, Rogier Versteeg, Ingrid Øra, Kristian W. Pajtler, Ludger Klein‐Hitpaß, Steffi Kuhfittig-Kulle, Eric Metzger, Roland Schüle, Angelika Eggert, Reinhard Buettner, Jutta Kirfel	369
20	Expression of Prenylated Rab Acceptor 1 Domain Family, Member 2 (PRAF2) in Neuroblastoma: Correlation with Clinical Features, Cellular Localization, and Cerulenin-Mediated Apoptosis Regulation 2007 ·Clinical Cancer Research ·Dirk Geerts, Christopher J. Wallick, (unknown), Jan Köster, Rogier Versteeg, (unknown), André S. Bachmann	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact